Phase III trial shows that VeriStrat identified patients likely to respond to erlotinib (Tarceva.)
Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone , M.D., Ph.D.
Biodesix's CEO, David Brunel, will present at the 2010 Personalized Medicine Partnerships conference, Wednesday, February 24th, at 11:00 a.m. eastern time.
Biodesix announced today that it has completed $10 million in Series B-1 financing round. The financing was led by existing shareholders and board members.
Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University will be presenting data on Veristrat at the 45th Annual Meeting of ASCO.
Biodesix announces the U.S. commercial availability of VeriStrat.
Biodesix announced that Paul J. Beresford has joined the Company as Vice President, Business Development and Strategic Marketing.
Biodesix, Inc., is pleased to announce receipt of a CLIA registration which allows the company to commercially market Veristrat® .
Biodesix announced today that Douglas E. Swan has joined the company as Vice President, Commercial Operations, reporting directly to David Brunel, CEO